Related Experiment Videos
[Clinical evaluation of cefpiramide in pediatric]
Insights
Cefpiramide (CPM), a broad-spectrum cephalosporin, effectively treated bacterial infections in 20 children, achieving a 17/20 cure rate. This antibiotic shows promise for pediatric infections, with manageable side effects like diarrhea.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Context:
- Bacterial infections pose significant health risks in children.
- Broad-spectrum antibiotics are crucial for treating diverse pediatric infections.
- Evaluating new antibiotics like Cefpiramide (CPM) is essential for expanding treatment options.
Purpose:
- To assess the safety and efficacy of Cefpiramide (CPM) in pediatric patients.
- To identify the spectrum of bacterial pathogens susceptible to CPM.
- To determine the pharmacokinetic profile and adverse reactions of CPM in children.
Summary:
- Cefpiramide (CPM), a novel cephalosporin, was administered to 20 children with various bacterial infections, including pneumonia, meningitis, and UTIs.
- Seventeen out of twenty patients achieved clinical cure, with key pathogens like H. influenzae and P. aeruginosa being susceptible.
- CPM exhibited a serum half-life of 2.4–4.1 hours; diarrhea was the most common adverse event, occurring in 4 cases.
Impact:
- Cefpiramide (CPM) demonstrates significant efficacy in treating a range of bacterial infections in children.
- The study supports the use of CPM as a viable therapeutic option for pediatric bacterial infections.
- Divided dosages (2-3 times daily) are sufficient for maintaining effective serum levels of CPM.
Abstract:
Cefpiramide (CPM), a new broad-spectrum cephalosporin antibiotic with good antipseudomonas activities, was evaluated for its safety and efficacy in 20 children with bacterial infections. The diagnoses of the patients included pneumonia (10), acute bronchitis (1), streptococcal pharyngitis (1), purulent cervical lymphadenitis (1), urinary tract infections (2), acute enterocolitis (1), infections in agranulocytosis and acute leukemia (2), and acute purulent meningitis (2). Of the 20 patients, 17 were cured by the CPM therapy. The main etiologic pathogens were H. influenzae, P. aeruginosa, P. fluorescens, S. pneumoniae and E. coli. The serum half-life of CPM was 2.4 to 4.1 hours after an intravenous bolus injection. As an adverse reaction, diarrhea was encountered in 4 cases, and 1 of them experienced severe watery diarrhea with significant fecal colonization of K. oxytoca. The data suggest that CPM is an effective antibiotic when used in children with susceptible bacterial infections. Administrations divided in 2 to 3 dosages will be enough to maintain effective serum levels.